Introduction
Genome alterations are a hallmark of cancer (Albertson et al., 2003; Pinkel and Albertson, 2005) . Several microarray-based techniques can be used to identify copy number changes in the genome at an unprecedented high resolution, from the megabase range down to a few tens of kilobases. These techniques include array comparative genomic hybridization (array-CGH), the use of cDNA arrays or oligonucleotide arrays and single nucleotide polymorphism (SNP) arrays (see Ylstra et al., 2006 for a review of the various platforms). The identification of genome alterations is useful in several ways. First, the characterization of these copy number changes can provide insight into tumor progression mechanisms. Second, this method can be used to identify genes involved in tumor progression: tumor suppressor genes and oncogenes are thought to be located in regions of loss and gain, respectively. Finally, variation in genomic alterations could be used to classify tumors molecularly, facilitating the diagnosis of new patients and assessments of their prognosis.
Many studies have been carried out on bladder cancer (Veltman et al., 2003; Blaveri et al., 2005; Stransky et al., 2006) , brain cancer (Bredel et al., 2005; Kotliarov et al., 2006) , breast cancer (Pollack et al., 2002; Fridlyand et al., 2006) , colon cancer (Douglas et al., 2004; Nakao et al., 2004) , liver cancer (Patil et al., 2005) , lymphoma (de Leeuw et al., 2004) , neuroblastoma (JanoueixLerosey et al., 2005; Mosse et al., 2005) , mouth cancer (Snijders et al., 2005) , pancreas cancer (Gysin et al., 2005) and replication timing (Woodfine et al., 2004; Janoueix-Lerosey et al., 2005) . Comparisons of the results of experiments from different laboratories, on different types of cancer, are required to validate results or hypotheses and to improve our understanding of the recurrent alterations involved in cancer. To our knowledge, no database allows today comparison in a rigorous way, that is no database have solved the question yet of how to make heterogeneous array copy number data comparable. We have, therefore, defined and carried out a protocol for homogeneous pretreatment of DNA copy number data and integration into ACTuDB (Array CGH Tumor DataBase) -a database compiling published array-CGH datasets that can be used for the browsing, visualization and analysis of tumor profiles via a user-friendly interface. In the Results section, the user interface, several analysis scenarios and meta-analyses are described. We then describe in the Materials and Methods section the various datasets available in ACTuDB and present how these data have been analysed with our algorithms to allow direct comparisons.
Results
Access and data analysis Data browsing in ACTuDB is based on VAMP software (La . VAMP is a graphical user interface for the visualization and analysis of array-CGH, transcriptome and other molecular profiles. We describe below the way in which data are organized, visualized and queried.
Data organization. Datasets are stored as 'projects' under the name of the first author and the year of publication. Within a project, the user can access the data either in 'Chromosome' mode (only the data for one particular chromosome are loaded) or in 'Genomic' mode (the profiles for all the concatenated chromosomes are loaded). The database loads and compares data from different projects, possibly corresponding to different array technologies or with different array designs.
Data visualization. VAMP software offers several possibilities for visualization, for example, the classical CGH karyotype view (see Figure 1 ) and genome-wide multitumor comparison views (see Figures 2-5) are available, facilitating the comparison of different arrays. Additional information for each clone or DNA region can be retrieved interactively from various public databases, through external links (NCBI, UCSC, Ensembl). We advise the reader to refer to the VAMP documentation available at the following URL: http:// bioinfo.curie.fr/vamp/doc.
Transverse analysis of array-CGH experiments
Users can easily carry out transverse analyses for a set of tumors from one or several projects. We present here three scenarios of potential interest to biologists. 
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Finding informative genomic regions. The identification of systemic alterations within a set of tumors is central to the analysis of CGH array data for two reasons. First, it can pinpoint new candidate genes, as tumor suppressor genes and oncogenes are thought to be present in regions of loss and gain, respectively. Second, some alterations may be significantly correlated with clinical phenotype and may therefore be useful for diagnosis and prognosis. The simplest way to identify informative regions is to work at the probe level. For each probe, the fraction of tumors with gains and losses over the dataset is displayed in the FrAGL view (see Figure 6 ). Instead of looking for individual probes carrying genome alterations, it is often fruitful to consider the geography of the genome and to look for whole regions. Rouveirol et al. (2006) have described algorithms for this analysis (see Figure 4) , and defined two categories of regions, included in ACTuDB:
Minimal regions of gain (or loss) correspond to the intersection for all tumors of the gained (or lost) regions. These regions are minimal, in that no breakpoint evidence is available to narrow the region further. Recurrent regions of gain (or loss) are defined as regions gained (or lost), with the same extremities (breakpoint positions), in a sufficient number of tumors. for all its probes by the GLAD algorithm; the status of a region is loss, normal, gain or amplicon, and is also assessed by GLAD). It is also possible to cluster the data based on the minimal/recurrent regions of alteration described above or on user-defined regions. The use of region status rather than information for all probes has two advantages. It eliminates redundancy between contiguous probes and gives the same weighting to each region, which is important because very small regions (such as amplicons) may be highly relevant for diagnosis/prognosis. This approach also makes it easy to provide a biological interpretation for clustering, as it is generally based on less than a hundred regions rather than thousands of probes. It should be noted that if users wish to cluster data from different projects with different designs, the only way to do this is to make use of regions.
Comparison of array-CGH and transcriptome data. Such comparisons are possible when the available transcriptome profiles have been integrated into the database. This is the case for the dataset of Pollack et al. (2002) , Patil et al. (2005) and Stransky et al. (2006) . The user can investigate whether gene expression displays particular alterations. Typically, the biologist will search for genes overexpressed in amplified regions or underexpressed in lost regions (see Figure 7 ).
Comparison of array-CGH and loss of heterozygosity data. In the dataset of Kotliarov et al. (2006) , both the copy number and loss of heterozygosity (LOH) have been studied with the Affymetrix GeneChip s Human Mapping 100K SetS. In Figure 8 , displayed are the DNA copy number profiles for chromosomes 10 and 13, and corresponding LOH profiles for sample HF0505 
Xba. For chromosome 10 the DNA copy number is diploid, whereas the LOH profile gives a strong evidence of loss of heterozigosity; this leads to the conclusion that chromosome 10 is isodisomic. For chromosome 13, LOH profile confirms the loss region identified on the DNA copy number profile.
Meta-analysis examples
We present here two meta-analyses examples on colon and bladder cancer. The detailed guidelines to perform these analyses are available as Supplementary Information.
Comparison of the frequency of alterations in two colon datasets. For each probe, the fraction of tumors with gains and losses over the Nakao et al. (2004) Example of informative genomic regions for 37 colorectal cancers from Douglas et al. (2004) . Genome alterations already reported by Douglas et al. (2004) were identified by our software (alterations are represented by vertical bandings ranging from dark to light pink for gain regions, dark to light green for loss regions and blue for amplified regions -amplicons are arbitrarily defined here as regions with log 2 -ratio>2). These alterations include gain of chromosomes 20, 13, 8q and loss of 8p, 18q or 17q11.2-q12 amplification as reported by Douglas et al. (2004) , gain of chromosome 7p and loss of chromosomes 4, 14q, 15q, 17p, 21q and 22q. The left panel shows the alterations identified on chromosome 8 with respect to cytogenetic banding.
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given as Supplementary Information (gene-list.pdf file); among them we can mention some of them involved in human tumors: E2F3, CDKAL1, SOX4 on chromosome 6, COX6C on chromosome 8 and CCND1 on chromosome 11. We then focus on the chromosome 6 analysis using only the Stransky et al. (2006) dataset to compare the genome alterations with respect to gene expression level. E2F3 gene expression was found to be highly correlated with DNA copy number level (correlation ¼ 0.88). This correlation was already reported by Hurst et al. (2004) .
Discussion
ACTuDB is a database that compiles array-CGH profiles and clinical data for tumors and can be browsed using VAMP software. All data in ACTuDB have been homogeneously pretreated as microarray probe mapping, breakpoint detection and gain/loss assignment. When available, expression data can also be compared with the genomic profiles. Transverse analysis can be carried out, by searching for minimal/recurrent alterations and compare their frequency between different projects or identifying subgroups of tumors with clustering techniques. Informative regions can be compared with genome annotations, such as gene position, to pinpoint candidate genes or with replication timing experiments. ACTuDB provides a user-friendly interface with more advanced analysis algorithms than existing databases (Baudis, 2006) . It also offers the possibility of adding other types of genome annotations potentially relevant for biologists. The database currently contains BAC, cDNA and oligonucleotide array data but can accept any kind of profile related to DNA copy number obtained with different platforms. In addition, any kind of molecular profile can be incorporated into ACTuDB, provided that data are available for genome position and there is a quantitative value to plot. Typical molecular profiles that can be integrated into the database include DNA copy number data, transcriptome data, ChIP-on-chip (Chromatine Immuno Precipitation) data and LOH data. We encourage our colleagues to submit their datasets to ACTuDB upon publication. They should contact us at actudb@ curie.fr and follow the guidelines provided at http:// bioinfo.curie.fr/actudb/. 
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Materials and methods
Data content
The data integrated into ACTuDB have been collected from available published data for the analysis of tumor genomic profiles by BAC, cDNA array-CGH or SNP arrays. The datasets are summarized in Table 1 and are presented more in detail in what follows.
Array-CGH datasets for cancers. The datasets in ACTuDB consist mostly of DNA copy number profiles for tumors of various origins as listed below (bladder, brain, breast, colon, liver, lymphoma, mouth, neuroblastoma and pancreas). Associated clinical and gene expression data have also been included in the database, when available.
Bladder cancer: copy number changes were studied in bladder tumors at different stages (Veltman et al., 2003) , and small regions with high levels of amplification or homozygous deletion were identified. In a study of 98 tumors, Blaveri et al. (2005) confirmed the alterations reported by Veltman et al. (2003) and identified additional alterations. Various statistical analyses demonstrated that copy number variation between pairs of known oncogenes and tumor suppressor genes was associated with changes in pathways known to be involved in bladder cancer (retinoblastoma and p53-MDM2 pathways). Stransky et al. (2006) proposed an approach for identifying candidate regions controlled by epigenetic mechanisms in cancer and for the characterization of one of these regions combining DNA copy number data and transcriptome data. Genome annotation data. Comparisons of genomic profiles with genomic annotation of any kind can help to elucidate the mechanisms involved in tumor progression. In ACTuDB, the user can visualize annotations, such as human gene structure, microRNA genes and genomic variants. Moreover, the results of two replication timing studies are provided. It may be interesting to compare breakpoint locations with replication timing pattern, as it has been suggested that chromosome breakpoints occur preferentially within early replicating regions (evidence to support this hypothesis has been obtained for neuroblastoma (Janoueix-Lerosey et al., 2005) ). The annotation data are detailed below:
Gene structure: the structural profiles of genes are updated from the UCSC Genome Browser (http://genome.ucsc.edu; Karolchik et al., 2003) (release hg18). All the information available for the gene, such as its name, position, intronexon structure and alternative splicing variants, are provided. Coding exons are shown as red blocks and introns, as horizontal red lines connecting the exons. The 5 0 and 3 0 untranslated regions (UTR) are displayed in dark green and a lighter green, respectively. Genomic variants: The Database of Genomic Variants (http://projects.tcag.ca/variation), which was first described by Iafrate et al. (2004) , includes genomic variants -defined as DNA regions larger than 1 kb and presenting copy number variation among a panel of unrelated individuals. When available, a list of diseases previously shown to be associated with this region is provided. MicroRNA, which was first described by Lee et al. (1993) , is now considered to be a major factor in cell regulation. MicroRNA expression can affect the cell cycle and survival mechanisms. MicroRNA loss or amplification has been reported in several types of cancer (Calin and Croce, 2006) , and microRNA expression profiles can be used to classify human cancers (Lu et al., 2005) . We have collected the microRNA data from the miRBase Sequence Database (http://microrna.sanger.ac.uk/sequences) (Release 9.0) of the Sanger Institute (Griffiths-Jones, 2006) in ACTuDB. Figure 7 Array-CGH (top profile) and expression ratio (second profile in descending order) of the same human tumors. The expression ratio was computed from Affymetrix U95 array of a bladder tumor sample and of a reference sample with no alteration on chromosome 11 . This confrontation pinpoints the probable implication of the gene cyclin D1 and fibroblast growth factor 3 in this tumor. The second profile is the ratio of the tumoral transcriptome array to the reference transcriptome profile.
Replication timing: Woodfine et al. (2004) suggested that array-CGH technology could be used to assess the replication timing of sequences during the S phase of the cell cycle. They used human lymphoblastoid cells and found a positive correlation between replication timing and various genome parameters, including GC content, gene density and transcriptional activity. Janoueix- Lerosey et al. (2005) also assessed the replication timing pattern of seven neuroblastoma cell lines and obtained similar results. They also found that the breakpoint frequency in 28 neuroblastoma cell lines was higher in early replicated regions than elsewhere.
Protocol for array pretreatment before integration into ACTuDB Probe mapping. A pipeline has been developed for mapping the probes onto a common human genome sequence reference: for each publication, the genome position is based on the last Working Draft version (current version is 36.1), with updating for each new release. The microarray data collected in ACTuDB were collected with three different types of probe, each involving a specific mapping process, as described below:
BacEnd clones were mapped, using information from public databases and an internal database from Institut Curie. The Figure 8 DNA copy number profile of chromosome 10 (top profile) and corresponding LOH profile (second profile from top), and DNA copy number profile of chromosome 13 (third profile from top) and corresponding LOH profile (bottom profile) for sample HF0505 Xba from the Kotliarov et al. (2006) dataset. For DNA copy number, the results of the GLAD algorithm are displayed (yellow correspond to normal region and green to loss region). For LOH profile log 10 (P-value) from Affymetrix software is displayed (this log 10 (P-value) is small for heterozygous regions and large for LOH regions): blue regions correspond to LOH and red regions do not show LOH.
ACTuDB database P Hupé et al mapping process consists of four-ordered steps, with each step corresponding to a database query. We used the information from the first database in which the probe appeared, ignoring all other databases. The databases were searched in the following order: (i) the UCSC Genome Browser annotation database (release hg18) (Karolchik Affymetrix probes sets were mapped from the UCSC Genome Browser annotation database (hg18) for expression arrays and from the SANGER/DECIPHER database for SNP arrays: the average of mapped probes sets were 94.8 and 100%, respectively.
The percentage of mapped probes for each publication is given in Table 2 .
Breakpoint detection. Genomic profiles were analysed using the GLAD algorithm (Hupe´et al., 2004) . GLAD identifies chromosomal regions with same DNA copy number, delimited by breakpoints. A label (Gain, Normal, Loss or Amplicon) is assigned to each region, based on its median DNA copy number. Amplicons are defined as probes with a signal ratio greater than 2. Outliers are also detected and correspond to probes with a signal value significantly different from the region in which they lie. The GLAD algorithm was also used to analyse the replication timing experiments, but with other parameters, as described by Janoueix- Lerosey et al. (2005) .
Hardware requirements and implementation
ACTuDB is based on a client-server architecture. On the client side, a Java-enabled HTML 4.0-compliant browser (Firefox, Safari, Internet Explorer) is required. Users must also configure their Java Virtual Machine according to the instructions given at http://bioinfo.curie.fr/actudb/. The user's computer must have at least 512 Mb of memory. On the server side, ACTuDB combines an XML repository with a dynamic web interface written in HTML and a Java applet. The website is powered by an Apache server. Blaveri et al. (2005) 92.9 Bredel et al. (2005) 91.7 Gysin et al. (2005) 92.6 Janoueix- Lerosey et al. (2005) 97.4 Mosse et al. (2005) 61.7 Patil et al. (2005) 92.8 Snijders et al. (2005) 93.2 de Leeuw et al. (2004) 71.5 Douglas et al. (2004) 99.3 Nakao et al. (2004) 93.0 Woodfine et al. (2004) 99.8 Veltman et al. (2003) 74.2 Chen et al. (2002) 83.8 Pollack et al. (2002) 88.5 Snijders et al. (2001) 89 
